On Deck For Alnylam: Three Phase III Starts In 2025
The RNAi specialist outlined plans to initiate three Phase III trials this year – two for nucresiran in ATTR amyloidosis and one for zilebesiran for hypertension – during an R&D day in New York.
The RNAi specialist outlined plans to initiate three Phase III trials this year – two for nucresiran in ATTR amyloidosis and one for zilebesiran for hypertension – during an R&D day in New York.